Sebaceous hyperplasia: systemic treatment with isotretinoin
AUTOR(ES)
Tagliolatto, Sandra, Santos Neto, Octavio de Oliveira, Alchorne, Maurício Mota de Avelar, Enokihara, Mauro Yoshiaki
FONTE
An. Bras. Dermatol.
DATA DE PUBLICAÇÃO
2015-04
RESUMO
The study aimed to verify the therapeutic action of isotretinoin in the treatment of sebaceous hyperplasia. During two months, 20 patients with sebaceous hyperplasia took isotretinoin at a dosage of 1mg/kg per day. Their skin lesions were counted and photographed before and after treatment and re-evaluated two years later. The average number of sebaceous hyperplasia lesions before treatment was 24 per patient. At the end of two months of therapy, the number of lesions decreased to 2 per patient. The statistically analyzed data showed a reduction in the number of lesions following isotretinoin use (p < 0.05). Two years after the end of the treatment, the average number of sebaceous hyperplasia lesions was 4 per patient. There were no severe side effects. Thus, the data analysis suggests that isotretinoin is a safe and effective drug for treating the disease under study.
Documentos Relacionados
- Benign prostatic hyperplasia: clinical treatment can complicate cataract surgery
- Bilateral adrenal medullary hyperplasia: a clinicopathological entity.
- Finasteride in the treatment of clinical benign prostatic hyperplasia: A systematic review of randomised trials
- Oral focal epithelial hyperplasia: report of five cases
- Long term psychological outcome for women with congenital adrenal hyperplasia: cross sectional survey